Вы находитесь на странице: 1из 5


OBJECTIVE Challenging opportunities in chemistry, biochemistry, food chemistry a
nd nutrition that emphasize innovation in all technical capacities including ana
lysis, problem solving, leadership, building of processes, infrastructural devel
opment and teamwork.
Skills: A powerful problem solver across multiple chemical, biological, physical
, and mathematical disciplines: Skilled and diversified chemist/biochemist with
expertise in separations, spectroscopy, analysis, synthesis, derivatizations, fo
od chemistry and nutrition with extensive experience in instrumentation, analyti
cal methods development and validation for complex matrices (e.g. foods, botanic
als, nutritional supplements, highly regulated contaminants); cGMPs; new product
development; formulation incompatibilities and shelf-life studies; food ingredi
ent design; protein & peptide chemistries; pharmacology
Personal: Affable; demonstrated record of creativity, motivational communicator,
proactive organizer, team player; incisive, but decorous leader; consistent 360
high-scorer for integrity, knowledge, high achievement, and helpful to others
Director of Technical Services; 10/2007-5/2008
* Directs all departments of QC and R&D Chemistry, Microbiology, and Stability;
consults on all development, stability, analytical, physical, and microbiologica
l issues for home care, personal care, nutritional and cosmetic product lines.
* This was a temporary opportunity I couldn't refuse; restructured/revitalized a
laboratory with profound needs!
* Completed construction of laboratory annex: 2000 ft2 stability chamber, HVAC,
300 additional amps, network, plumbed gases/vacuum, offices, phones
* Consolidated separate R&D and quality laboratories that centralized analytical
functions under same roof, maximized instrument usage, minimized space and cost
of utilities, and eliminated administrative redundancies; funded and implemente
d purchase of strategically-designed LIMS
* Purchased and implemented comprehensive NIR identification program for raw mat
erials (personal care, home care, nutritional supplements) against real-world, a
nalytically-verified references
* Restructured technically top-heavy organization with entry-level personnel cre
ating much-appreciated career-ladder hierarchy; implemented comprehensive cross-
training program; implemented analytical method development and validation progr
am replacing several dozen archaic methods while filling analytical voids that d
ecreased the huge prior outsourcing by 90%; consolidated eight stability cabinet
s into dedicated facility; validated/temperature-mapped cabinets and chamber; im
plemented real-time and accelerated stability programs
* Implemented: Preservative Efficacy Testing in Micro lab to supplant annual $40
0k PAT outsourcing; CIP validation for cross-utilization of facilities manufactu
ring both home-care and consumable goods; lab infrastructure and practices to ac
hieved full cGMP compliance
eider Nutrition Int'l prior to 2005)
Director of Analytical Sciences, 2000-10/2007
Laboratory Manager, Analytical Sciences, 1999-2000
Senior Chemist, Analytical Sciences, 1997-1999
* Directs all Chemistry (QC, R&D, and Stability) functions and Microbiology depa
rtments; consults on all corporate chemical and analytical issues.
* Built from an empty 10,000-ft2 shell to what is now reputed as the finest labo
ratory in the nutritional supplement industry, providing comprehensive chemical
and microbiological services for over 4000 raw materials and ca 700 finished pro
ducts for all business units (tablets, capsules, powders, nutrition bars, bevera
ges); Hires and oversees training of all associates; current staff of 25 (19 deg
* Selected and purchased all instrumentation, e.g., LC-MS, ICP-MS, GC-MS, HPLC,
AA, FT-mid and near IR and other spectrometers; full proximate suite; microtiter
plate reader, washer; titrators.
* Directs method developments for analysis of hundreds of analytes (vitamins, me
tabolites, botanicals, micronutrients, proximates, minerals, contaminants, heavy
metals, etc.) in thousands of complex matrices; Consults on all chemistry issue
s: R&D, stability, formulations, side-reactions, vendor disputes, contamination,
identification of unknowns, adulterations, customer complaints
* Lab performed >42,000 chemical analyses (*3% RSDs) in-house last year with a m
ean 3.2-day turntime, plus >40,000 in-house micro analyses last year
* Consecutively exponentiates lab's analytical output for last several years (wi
thout substantive increase in resources!) saving $9 million in outsource costs l
ast year alone
* Over 100 new products launched as member of new product development team with
methods developed for all raw material COA and finished product label claims. I
dentifies millions of dollars worth of subpotent raw materials (rejected) and hu
ndreds of thousands of dollars subpotent finished product (for rework or disposi
tion) annually
* Organized infrastructural operations implementing them into SQL-based LIMS (wr
itten by in-house IS) that became "operation critical" software employed by mult
iple departments; Designed trend analysis and skip-lot testing algorithm for Sup
plier Certification and traceable method OOS algorithms (programmed by IS), each
implemented in LIMS
* Developed accelerated and real-time stability programs for both new product de
velopment and product maintenance, respectively; designed comprehensive data red
uction database (written by in-house IS) that mediates all aspects of stability
* Designed program of raw material identification by FT-NIR in accordance with 2
1 CFR 11 and with up-link to LIMS
* Installed labwide UPS backup for all instruments and computers, also HPLC clie
nt-server network for 21 CFR 11 compliance and daily e-data backup
* Administrates writing of methods and SOPs and their approval by routing in ele
ctronic document control; numerous hundreds of methods reviewed and maintained.
Maintains compliance with USP and NSF GMPs (nutritional supplement) and TGA GMP
s (OTC pharmaceutical level) and conducted multiple onsite contract lab audits
Facility), Tooele, UT
Shift Supervisor, 1996-1997 (The R&D position I aspired to was dissolved by the
treaty, so I resigned.)
* Supervised all aspects of instrument operation; quantitative and qualitative a
nalyses on various nerve and blister agents, extracts, process emissions, and ai
r monitoring in compliance with OSHA, RCRA, county, state, federal, and treaty r
Research Assistant Professor, Department of Biology (with concurrent appointment
in Neuroscience Program, '92-'95), University of Utah, Salt Lake City, UT (1991
-1995). Coinvestigator continuing postdoctoral work; supervised undergraduate,
graduate, and postdoctoral students.
Postdoctoral Research Fellow, Department of Biology, University of Utah, Salt La
ke City, UT (1989-1991) Mentor, Distinguished Prof. Baldomero Olivera, voted 200
7 Scientist of the Year by the Harvard Foundation. Bioassay, purification, and
amino acid sequence determination of various polypeptide ligands. Synthesized p
olypeptides, folded, radiolabeled, site-selectively incorporated nitrene precurs
ors, targeted to neuronal receptors and photolyzed, thus photoaffinity-labeling
receptors. Purified and characterized novel neuronal receptor subtypes. Devel
oped novel affinity columns, radioligand binding assays, techniques for membrane
protein purification. 2D-NMR structure determination of polypeptide ligands.
* Represented US Pharmacopoeia presenting at the Vitamin Methodology Workshop, N
IH/ODS, Gaithersburg, MD (July 7-8, 2008)
* Appointed by AOAC Official Methods Board to chair the AOAC New Business Model
Development subcmte (Feb 2007)
* Reappointed for second term as member of AOAC Official Methods Board and as Ch
airman of the AOAC Methods Committee on Dietary Supplements (Committee K) (April
2006 to June 2009)
* Appointed member of AOAC Presidential Task Force on Dietary Supplements (Apri
l 2006 to June 2009)
* Appointed one of six members of the US Pharmacopoeia 2005-2010 Expert Committe
e, Dietary Supplements-Non-Botanicals (April 2005 to '10)
* Appointed Horwitz Advisor by AOAC Executive Director to counsel Analyte Indust
ry Group chairs in technology and AOAC protocol (Nov 2004 to present)
* Appointed member of numerous AOAC Expert Review Panels, e.g., "Ultra-Low Level
Pesticide Detection in Soft Drinks" that convened in New Delhi, Nov. 2006. [In
dia has retained AOAC to validate a method that will quantify hundreds of pestic
ide residues in dozens of soft drink matrices at the 0.1 ppb level! With simila
r concerns having spread into Europe, Coca Cola and Pepsi are funding this effor
t to be harmonized worldwide.] (Nov. 2005)
* Appointed by AOAC Executive Director to AOAC Methods Committee on Dietary Supp
lements (Cmte K) that comprises eleven members; contracted by FDA/NIH to adminis
ter the development and validation of methods for the analysis of dietary supple
ments. (May 2002 to Dec 2004). Reappointed second term (Dec 2005 to present)
* Appointed member of AOAC Ingredients Ranking Sub-Task Group, a six-member comm
ittee tasked annually to identify nutritional supplement analytes for methods to
be collaboratively validated by AOAC Committee K, above. (July 2002 to present
* Editorial peer-reviewer, J. Food Science and J. AOAC (2002 to present); Anal.
Bioanal. Chem. (2007 to present)
* Member of Chondroitin Sulfate Science Committee; my method was selected. Wrot
e and validated method for Institute of Nutraceutical Advancement (INA Method 12
0.002), USP 26/NF 21 monographs, and submitted to AOAC for collaborative study p
er FDA/NIH initiative (pending).
* Member, BSE Task Force, Council for Responsible Nutrition (Washington DC, Febr
uary 14; 2001 to present)
* Appointed representative for Botanicals/Quality Standards Committee of the Cou
ncil for Responsible Nutrition (2000 to present)
* Member Industry Steering Committee to write report to ODS of the National Inst
itutes of Health to standardize and characterize nutritional supplements for cli
nical research. (March 2001)
* Appointed Associate Referee for Ephedra Alkaloids by AOAC Executive Director t
o direct development of AOAC analytical method for ODS/NIH. (Declined appointme
nt when INA elected ephedra to roster.)
* One of a five-coinvestigator team (Toto Olivera, PI) recruited to occupy a flo
or of the newly constructed Institute of Biosciences and Technology of Texas A&M
University in the Houston Medical Center (1992). We declined the offer, but wi
th the U of U counter-offer, four of us designed what became the largest researc
h lab on the U of U campus.
* Phi Lambda Upsilon (academic chemical society), sponsored distinguished speake
rs (e.g., Linus Pauling) on campus
* Listed in American's Registry of Outstanding Professionals and various Who's W
ho registries
* American Chemical Society and International Union of Pure and Allied Chemistry
* American Society of Mass Spectroscopists
* AOAC International
* U.S. Pharmacopeia 2005-2010 Expert Committee, Dietary Supplements-Non-Botanica
* Institute of Food Technologists, Professional Member
* American Oil Chemists' Society
* 18 Journal articles, 2 reviews, 1 book chapter (all refereed), and 1 patent
* Numerous hundreds of analytical methods; dozens employed worldwide, several pu
blished in US Pharmacopeia (others pending), AOAC (pending), Institute of Nutrac
eutical Advancement, etc.
* Numerous abstracts and institute/campus/conference presentations
* Numerous White Paper contributions to industry publications, fitness magazines
, and promotional literature
Ph.D., Biochemistry, University of Utah, 1989 [Protein structure: peptide synth
esis, receptorology, NMR, Raman, CD]
M.S., Cell and Developmental Biology, Brigham Young University, 1981 [Cartilage
B.S., Biology, Brigham Young University, 1979 [Human physiology]
* Chemometric Techniques (ACS); Richard Kramer; President, Applied Chemometrics,
Inc., Boston, MA (8/21/07)
* Solid Phase Extraction Technology and Techniques; Frederick E. Klink, PhD, ACS
, San Diego, CA (3/13/05)
* Regulatory Compliance of D.S. Laboratories, Salt Lake City, UT; AAC Consultin
g (6/17-6/18/04)
* Effective Management of Chemical Analysis Laboratories (ACS), Chicago, IL; Cla
ude Lucchesi (founding editor of the journal (3/6-3/7/04)
* Nutraceutical Testing & the USP and Developing & Validating Nutraceutical Test
Methods; Richard Lindauer, PhD, sponsored by ChromaDex; Secaucus, NJ (5/7/01)
* Dietary Supplement Labeling Compliance, Salt Lake City, UT; AAC Consulting (10
* Dietary Supplement GMPs, San Francisco, CA; AAC Consulting (6/29-6/30/00)
References available upon request. Confer attached biography for earlier accomp
Academic Biography for Rick Myers, PhD
(Compliment to resume)
B.S., Biology, Brigham Young University
M.S., Biology, Brigham Young University
Molecular and Cellular Biology; Thesis on cartilage biochemistry
-Biochemistry/Biophysics, Washington State University, transferred to UU after t
wo years
Raman and IR spectroscopic determination of protein secondary structure
Ph.D., Biochemistry, University of Utah
I'm an accomplished chemist and biochemist in the neurosciences with extensive
experience in analyte extractions, purifications (including numerous large nativ
e complexes), selective proteolysis, fraction isolation, amino acid and sequence
analyses, selective chemical modifications, synthesis, etc., which I've applied
to various aspects of receptorology and the neurosciences. I reference the fol
lowing review [Myers, R.A., L.J. Cruz, J. Rivier and B.M. Olivera (1993) Conus p
eptides as chemical probes for receptors and ion channels. Chemical Reviews 93:
1923-1936] in which are described some of the extensive chemistry, protein chem
istry, receptorology, and ligand-receptor binding studies performed by me while
working in the lab's of Bill Gray of dansyl chloride fame, and of B.M. "Toto" Ol
ivera who received the 2007 Scientist of the Year by the Harvard Foundation. [P
lease refer to the end of this letter where I briefly elaborate some of the spec
ific skills I developed in this work.] It may be of interest that some of Olive
ra's polypeptides are now being exploited as drugs:
* Prialt(R) (*-conotoxin MVIIA) is the first intrathecal analgesic approved in t
he US in more than two decades
* Conantokins-G and -T (two polypeptide ligands that I characterized) are now in
Phase II trials with potential antagonistic activity at one or more NMDA bindin
g sites.
The following is a brief review of my drug development research performed throug
hout my dissertation, postdoctoral fellowship, and university faculty tenure (de
scribed above):
* Isolated biologically active polypeptides toxins extracted from venom ducts of
marine snails and purified them by HPLC.
* Injected purified polypeptide toxins (IC and IP) into mice to determine if bio
logically-active phenotypes are exhibited.
* Hydrolyzed and amino acid analyzed, and performed Edman degradation to determi
ne the amino acid composition and sequence of the active polypeptides, respectiv
* Solid-phase synthesized bulk quantities of multiple polypeptide receptor ligan
ds by Merrifield synthesis, folded the polypeptides, and oxidatively cyclized (t
wo to three disulfides, toxin depending) into their active conformations, i.e.,
those with same LC retention times as native polypeptides.
* Prepared rat brain homogenates and natively detergent-extracted receptors.
* Radioiodinated the synthetic polypeptide ligands, developed multiple ligand bi
nding assays for both membrane-bound and detergent-solubilized receptors, then c
haracterized ligand binding kinetics and determined Kds, binding site stoichiome
tries, and competitive and noncompetitive binding of multiple drugs.
* Radioiodinated nitrene precursors (photoactivatable reporter groups).
* Selectively and covalently coupled said reporters at different topological loc
ations on the synthetic polypeptide ligands to create selectively-targeting rece
ptor probes of defined dimensionalities and structures.
* Synthesized various tethered-drug affinity sorbents with which I enriched rece
ptor extracts by affinity chromatography.
* Incubated selective probes (described above) with and allowed them to bind to
affinity-enriched receptors, then photolyzed to covalently label said novel rece
* Chromatographically and/or electrophoretically separated photoaffinity-radiola
beled receptor subunits and determined their molecular weights.
* Protease- and cyanogen bromide-digested purified labeled receptors subunits.
* Chromatographically resolved photoaffinity-labeled receptor polypeptide fragme
* Determined amino acid sequence of photoaffinity-labeled receptor fragments whi
le monitoring release of the radio-tagged amino acids.
* The above work was done initially with polypeptide toxins targeting acetylchol
ine receptors (AChR) that I purified to homogeneity from fish electroplax. Sele
ctive reporter placement allowed me to characterize the receptor site, subunit o
rientation, and binding orientation of the ligand (as PhD dissertation). I did
similar work with other toxins: marine snail and spider venoms that selectively
target voltage-activated calcium channels (as postdoc) and NMDA receptors (as Re
search Assist Professor).
* Acquired high-field 2D-NMR spectra of one of these active polypeptides (alpha-
conotoxin MI) that selectively targets AChR for its three-dimensional structure